Press Release – New York, NY – June 17, 2025 – Sichenzia Ross Ference Carmel LLP announced that it represented Jyong Biotech Ltd. (Nasdaq: MENS), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, in its $20 million initial public offering.
Joseph Stone Capital, LLC acted as the sole underwriter for the offering. The Joseph Stone team was led by Cathy Cao.
The SRFC team was led by partners Ross Carmel and Shane Wu, with associate Tomer Magid.
